Literature DB >> 17079379

Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues.

James T Ryaby1, Michael R Sheller, Benjamin P Levine, Dale G Bramlet, Amy L Ladd, Darrell H Carney.   

Abstract

The thrombin peptide, TP508, also known as Chrysalin (OrthoLogic, Tempe, Arizona), is a twenty-three-amino-acid peptide that represents a portion of the receptor-binding domain of the native human thrombin molecule that has been identified as the binding site for a specific class of receptors on fibroblasts and other cells. Preclinical studies with this peptide have shown that it can accelerate tissue repair in both soft and hard tissues by mechanisms that appear to involve up-regulation of genes that initiate a cascade of healing events. These events include recruitment and activation of inflammatory cells, directed migration of cells (chemotaxis), cell proliferation, elaboration of extra-cellular matrix, and accelerated revascularization of the healing tissues. Early preclinical dermal wound-healing studies showed that TP508 accelerated healing of both incisional wounds and full-thickness excisional wounds in normal and ischemic skin. In all of these studies, the accelerated healing was associated with increased neovascularization across the incision or in the granulating wound bed. Studies in a rat fracture model have also shown that TP508 accelerates the rate of fracture repair. Gene array analysis of fracture callus from control and TP508-treated fractures indicated that TP508 treatment was associated with an up-regulation of early response elements, inflammatory mediators, and genes related to angiogenesis. Similar to what had been seen in dermal wounds, histology from rat fracture callus twenty-one days after treatment indicated that fractures treated with TP508 had significantly more large functional blood vessels than did fractures in the control animals. In vitro studies support these in vivo data and indicate that TP508 may have a direct angiogenic effect by promoting the rate of new vessel growth. The results from phase-1 and phase-2 human clinical studies have shown a positive stimulatory effect of TP508 in the healing of diabetic ulcers and in the repair of fractures to the distal aspect of the radius. Collectively, these studies suggest that TP508 accelerates tissue repair by initiating a cascade of events that lead to an increased rate of tissue revascularization and regeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079379     DOI: 10.2106/JBJS.F.00892

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  11 in total

Review 1.  Commonalities Between COVID-19 and Radiation Injury.

Authors:  Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo
Journal:  Radiat Res       Date:  2021-01-01       Impact factor: 2.841

2.  Angiogenesis in bone regeneration.

Authors:  Kurt D Hankenson; Michael Dishowitz; Chancellor Gray; Mara Schenker
Journal:  Injury       Date:  2011-04-12       Impact factor: 2.586

3.  Radiomitigation and Tissue Repair Activity of Systemically Administered Therapeutic Peptide TP508 Is Enhanced by PEGylation.

Authors:  Scott D McVicar; Kempaiah Rayavara; Darrell H Carney
Journal:  AAPS J       Date:  2017-01-17       Impact factor: 4.009

Review 4.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

5.  Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine.

Authors:  Shizu Oyamada; Robert Osipov; Cesario Bianchi; Michael P Robich; Jun Feng; Yuhong Liu; Thomas A Burgess; Timothy M Bell; Michael R Sheller; Frank W Sellke
Journal:  J Pharmacol Exp Ther       Date:  2010-05-11       Impact factor: 4.030

6.  Dissection of the osteogenic effects of laminin-332 utilizing specific LG domains: LG3 induces osteogenic differentiation, but not mineralization.

Authors:  Robert F Klees; Roman M Salasznyk; Donald F Ward; Donna E Crone; William A Williams; Mark P Harris; Adele Boskey; Vito Quaranta; George E Plopper
Journal:  Exp Cell Res       Date:  2008-01-22       Impact factor: 3.905

7.  Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing.

Authors:  Brandon Beamer; Carolyn Hettrich; Joseph Lane
Journal:  HSS J       Date:  2009-09-09

8.  Systemic administration of thrombin peptide TP508 enhances VEGF-stimulated angiogenesis and attenuates effects of chronic hypoxia.

Authors:  Barbara Olszewska-Pazdrak; Darrell H Carney
Journal:  J Vasc Res       Date:  2013-04-16       Impact factor: 1.934

9.  Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015.

Authors:  Merriline M Satyamitra; Andrea L DiCarlo; Lanyn Taliaferro
Journal:  Radiat Res       Date:  2016-07-07       Impact factor: 2.841

Review 10.  The role of peptides in bone healing and regeneration: a systematic review.

Authors:  Ippokratis Pountos; Michalis Panteli; Anastasios Lampropoulos; Elena Jones; Giorgio Maria Calori; Peter V Giannoudis
Journal:  BMC Med       Date:  2016-07-11       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.